Life Sciences Forum Feb 2021

Quarterly Vanguard Forum for Life Sciences Leaders

This Forum was presented at the request of several of our Life Sciences Leaders members. We worked on two critical challenges for 2021: What do we need to know about Population Health to enable better therapies, faster AND what should we learn from the COVID 19 vaccines about accelerating development of other products?

Each session was led by fellow Life Sciences Leaders with deep experience in the topics. Cameron Durrant, Chairman/CEO Humanigen, Inc. was be the Forum Chair.


Session leaders for the mini-forums are highly experienced Life Sciences Leaders, board members, and top leadership experts. 
Advisory board members help us plan the forum agendas, which focus on the topics most important to Life Sciences Leaders. Board members include:

  • Carrie Cox, Chairman of the Board, NewCo

  • Cameron Durrant, Chairman and CEO, Humanigen

  • Amber Edwards, Chief Commercial Officer, Alastin Inc.

  • Vivek Ramaswamy, Founder and CEO, Roivant Sciences

  • Davidi Vortman, CEO, OnSight Medical


Making population health a competitive edge.

This session will look at how population health insights can be applied by life sciences companies to improve outcomes and performance. C-Suite executives and population health experts will catalyse discussion on how LS leaders and their teams can take advantage of the latest advantages in population health to drive performance.

Accelerating development: What should we learn from the COVID-19 vaccines and therapeutics?

Speeding up clinical trials: this is the holy grail of life sciences. This session will explore how we, as top leaders, can learn from the extraordinary innovations in development that created an array of COVID 19 vaccines within a year. What are the new tools and insights on which we should focus our teams? Do we need to fine tune clinical trial processes, or blow them up? Are there new and better models for processes with the FDA? What are our own roles, and should they change?




Korn Ferry
Debevoise&Plimpton Logo.png

Roivant Sciences is a valued contributor.